GLPwatch
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
NCT00877890 · Completed
Last updated 2026-05-28This clinical trial tested the effects of a weekly injectable medication called exenatide on blood sugar control in adults with type 2 diabetes over a 24-week period.
Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 254 people
Who can join Ages 18+ · all sexes
Timeline Started 2009-03 · est. completion 2010-01
Where 41 sites · United States
What this study is testing ClinicalTrials.gov NCT00877890 ↗
Description as written by the study sponsor.
This study will compare the effects of commercially manufactured exenatide once weekly and exenatide BID in subjects whose type 2 diabetes is managed with diet and exercise alone or with oral antidiabetic medications. The study will examine glycemic control (as measured by HbA1C), safety, and tolerability.
Treatments tested
- exenatide once weekly also known as BYDUREON Drug
subcutaneous injection, 2.0mg, once a week
- exenatide twice daily also known as BYETTA Drug
subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
| Main thing measured | Change in HbA1c From Baseline to Week 24 |
|---|---|
| Sponsor | AstraZeneca |
| Conditions studied | Type 2 Diabetes Mellitus |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00877890 ↗